Revisiting cardiac injury during acute heart failure: Further characterization and a possible target for therapy

Sean P. Collins, Peter S. Pang, Javed Butler, Gregg Fonarow, Marco Metra, Mihai Gheorghiade

Research output: Contribution to journalEditorialpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)141-146
Number of pages6
JournalAmerican Journal of Cardiology
Volume115
Issue number1
DOIs
StatePublished - Jan 1 2015

Funding

Dr. Collins receives research support from NIH / National Heart, Lung, and Blood Institute (NIH/NHLBI K23HL085387), Radiometer , Medtronic , Cardiorentis , Novartis , and The Medicines Company and serves as a consultant for Novartis, The Medicines Company, Trevena, BRAHMS, Bayer, Radiometer, Otsuka, Medtronic, and Intersection Medical. Dr. Pang (in the last year) receives research support from NIH , Abbott , and Alere , and serves as a consultant/honoraria for Cardioxyl, Insys, Intersection Medical, Janssen, Medtronic, Novartis, Trevena, and scPharmaceuticals. Dr. Butler receives research support from the National Institutes of Health , European Union , and the Health Resources and Services Administration , and serves as a consultant for Amgen, BG Medicine, Celladon, Ono Pharmaceutical, Trevena, Bayer, Medtronic, Novartis, CardioCell, and GE Healthcare. Dr. Fonarow receives research support from AHRQ (significant) and National Heart, Lung, and Blood Institute (significant), and serves as a consultant for Bayer (modest), Novartis (significant), Medtronic (modest), and The Medicines Company (modest). Dr. Metra serves as a consultant for Bayer, Novartis, and Servier. Dr. Gheorghiade from Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, Cardiorentis Ltd, Corthera, Cytokinetics, CytoPherx, Inc., Debiopharm S.A., Errekappa Terapeutici, GlaxoSmithKline, Ikaria, Intersection Medical, Inc, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Ono Pharmaceuticals USA, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals North America, Inc, and Trevena Therapeutics, and has received significant (>$10,000) support from Bayer Schering Pharma AG , Debiopharm S.A. , Medtronic , Novartis Pharma AG , Otsuka Pharmaceuticals , Sigma Tau , Solvay Pharmaceuticals , Sticares InterACT , and Takeda Pharmaceuticals North America .

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this